Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM326 in healthy volunteers
NCT04842201Phase 1Completed
- Sponsor
- Keymed Biosciences
- Start
- Apr 2021
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in asthma comparing CM326 with Placebo (2 arms). Primary endpoint: Number and severity of adverse events. Started Apr 2021; status: completed.
02
Drugs
CM326
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04842201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04842201.